Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $33.2 million.

  • Maxcyte's Total Liabilities fell 597.28% to $33.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.2 million, marking a year-over-year decrease of 597.28%. This contributed to the annual value of $33.2 million for FY2024, which is 799.84% down from last year.
  • Maxcyte's Total Liabilities amounted to $33.2 million in Q3 2025, which was down 597.28% from $29.0 million recorded in Q2 2025.
  • Maxcyte's Total Liabilities' 5-year high stood at $36.1 million during Q4 2023, with a 5-year trough of $13.6 million in Q3 2021.
  • Moreover, its 5-year median value for Total Liabilities was $31.8 million (2022), whereas its average is $29.5 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 13559.53% in 2022, then tumbled by 799.84% in 2024.
  • Maxcyte's Total Liabilities (Quarter) stood at $21.2 million in 2021, then skyrocketed by 54.01% to $32.7 million in 2022, then rose by 10.47% to $36.1 million in 2023, then decreased by 8.0% to $33.2 million in 2024, then decreased by 0.05% to $33.2 million in 2025.
  • Its Total Liabilities was $33.2 million in Q3 2025, compared to $29.0 million in Q2 2025 and $30.5 million in Q1 2025.